Emerging drugs for the treatment of dry eye disease

Abstract

Introduction: Dry eye disease (DED) is a common, age-related ocular condition that in its mildest forms causes bothersome symptoms of ocular discomfort, fatigue, and visual disturbance that interfere with quality of life and in its more severe forms causes chronic pain and fluctuating vision. Though it is highly prevalent and costs billions of dollars to manage, current treatments have largely been inadequate, making it a frustrating condition, both for physicians and patients alike.

Areas covered: This article will cover the recently discovered pathophysiology of DED that has prompted investigators to explore new molecules that target the core mechanisms that drive DED. These include anti-inflammatory/immune-modulatory drugs, secretagogues, lubricant, hormones, and autologous serum. Their potential mechanism of action and data from recent trials on efficacy/safety will be reviewed.

Expert opinion: The emerging drugs have a vast range of putative mechanisms of action that may not only provide symptomatic relief but may potentially break the vicious cycle of DED and provide long-lasting cure. Current and future research may change our perspective on DED and redefine its treatment algorithms.

Keywords::

• anti-inflammatory
• autologous serum
• dry eye disease
• hormones
• omega3
• secretagogues

Declaration of interest

Penny Asbell, MD, has received a research grant from lcon, Pfizer, and Bausch and Lomb in the past. She has been a speaker for Merck and has been a participating site in a multicenter trial sponsored by Topcon medical systems. For the remaining authors no conflict of interest is declared.

Notes